choose content

Choose content

Enter keywords to create a newsletter
create account

Create account

Enter your registration information
set preferences

Set preferences

Set up your newsletter name, delivery and time zone preferences
Hint: Enter different keywords to generate new results.

Now you can:

  1. Search the news index.
  2. Browse more than 1 million newsletters by category.
  3. Use preset newsletters:
    • Daiichi Sankyo Earnings

Daiichi Sankyo Earnings Newsletter
  • AbbVie Q1 Earnings Preview: No Repeat Of Last Year's Q1 Disappointment 18 Apr 2024 18:56 GMT

    … 26th. Analysts are forecasting earnings per share ("EPS… to worry, hence Q1 2024 earnings should be straightforward to interpret … in a partnership with Daiichi Sankyo to develop ADC's … deliver a set of earnings that surprises, and ultimately …

  • JNJ Earnings Forecast - Is Pharmaceutical Industry Set for Shake-up? 15 Apr 2024 23:38 GMT

    … see if its first-quarter earnings will shake up the Pharmaceutical … company’s adjusted net earnings and net earnings per share from continuing …  industry: GSK PLC ADR (GSK), Daiichi Sankyo Company, Limited (DSNKY), and Taro …

  • GLP-1 surge, oncology stars to power industry's earnings growth over the next 18 months: Moody's 15 Mar 2024 16:37 GMT

    … the industry’s overall earnings performance has been … Squibb, Roche, AstraZeneca and Daiichi Sankyo. Beyond 12 to 18 months … the potential to affect industry earnings, according to Moody… in 2026. Another potential earnings pressure is more patent …

  • Daiichi Sankyo Again Raises Enhertu Sales Forecast Driven by Non-US Growth 01 Feb 2024 13:23 GMT

    … to its third quarter earnings report for the fiscal … October 2023. According to Daiichi Sankyo’s presentation on Wednesday … business into consideration, Daiichi Sankyo reported a total revenue … As for pipeline updates, Daiichi Sankyo and partner AstraZeneca are …

  • Merck still on the hunt for billion-dollar deals, citing Prometheus and Daiichi Sankyo as examples 01 Feb 2024 16:34 GMT

    Mer­ck is still in pur­suit of deals of a sim­i­lar size and scope to the com­pa­ny’s ac­qui­si­tions of Prometheus Bio­sciences and Ac­celeron, and is will­ing to pay up to $15 bil­lion. It’s al­so still con­sid­er­ing small­er deals and …

  • Esperion Therapeutics, Inc. (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript 28 Feb 2024 13:53 GMT

    … (NASDAQ:ESPR) Q4 2023 Earnings Call Transcript February 27, 2024 … Esperion Therapeutics, Inc. beats earnings expectations. Reported EPS is $- … s Fourth Quarter 2023 Earnings Conference Call. At … to our collaboration with Daiichi Sankyo Europe, which marked the …

  • AstraZeneca PLC (NASDAQ:AZN) Q4 2023 Earnings Call Transcript 09 Feb 2024 16:26 GMT

    … NASDAQ:AZN) Q4 2023 Earnings Call Transcript February 8, … 2024 AstraZeneca PLC misses on earnings expectations. Reported EPS is … with this collaboration with Daiichi Sankyo, that you know very … sales in regions where Daiichi Sankyo books product sales. …

  • AstraZeneca Plc (AZN) Q4 2023 Earnings Call Transcript 08 Feb 2024 23:17 GMT

    … (AZN -4.55%) Q4 2023 Earnings Call Feb 08, 2024, 6 … started with this collaboration with Daiichi Sankyo, that you know very … payments including milestone payments to Daiichi Sankyo. For this year, we … Analyst More AZN analysis All earnings call transcripts

  • Merck & Co., Inc. (NYSE:MRK) Q4 2023 Earnings Call Transcript 02 Feb 2024 16:42 GMT

    … (NYSE:MRK) Q4 2023 Earnings Call Transcript February 1, 2024 … ; Co. Q4 Sales and Earnings Conference Call. [Operator Instructions] … slides, along with the earnings release, today’s prepared … to our collaboration with Daiichi Sankyo. Excluding this charge, …

  • Merck (MRK) Q4 2023 Earnings Call Transcript 01 Feb 2024 20:11 GMT

    … ; Company Q4 sales and earnings conference call. At this … These slides, along with the earnings release, today's … related to our collaboration with Daiichi Sankyo. Excluding this charge, … ; Company Q4 sales and earnings conference call. That concludes …

Satisfied with the content?

Continue to create your account.